Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Vicore Pharma Holding AB ( (SE:VICO) ).
Vicore Pharma announced its participation in the European Respiratory Society Congress 2025, where it will present new data from its Phase 2a AIR trial of buloxibutid for idiopathic pulmonary fibrosis (IPF). The trial results, supported by a synthetic control arm analysis, indicate a significant improvement in lung function, highlighting buloxibutid’s potential as a disease-modifying treatment. Additionally, Vicore will present findings on Almee™, a digital therapy aimed at improving life satisfaction for pulmonary fibrosis patients. These presentations underscore Vicore’s commitment to advancing treatments for respiratory diseases and may enhance its positioning in the pharmaceutical industry.
More about Vicore Pharma Holding AB
Vicore Pharma Holding AB is a clinical-stage pharmaceutical company focused on developing a new class of drugs for respiratory and fibrotic diseases, such as idiopathic pulmonary fibrosis (IPF). Their lead product, buloxibutid, is an oral small molecule angiotensin II type 2 receptor agonist, currently in a global Phase 2b trial. The company is publicly listed on the Nasdaq Stockholm exchange.
Average Trading Volume: 557,567
Technical Sentiment Signal: Hold
Current Market Cap: SEK2.37B
For an in-depth examination of VICO stock, go to TipRanks’ Overview page.